Chicago Law Firm Kenneth B. Moll & Associates Filed First Worldwide Class Action Lawsuit against Pfizer, Inc., on Behalf of All Consumers of Bextra

CHICAGO--(BUSINESS WIRE)--April 11, 2005--Kenneth B. Moll & Associates, Ltd.


MONDAY, APRIL 11, 2005 - 11:00am

70 W. Madison Ave., 50th Floor, Chicago, Illinois

(312) 558-6444

The law firm of KENNETH B. MOLL & ASSOCIATES, LTD. filed the first worldwide class action lawsuit against Pfizer, on behalf of all persons who died or were injured by the pain medication, Bextra. The suit accuses pharmaceutical giant Pfizer, Inc., of failing to properly research the known risks of Bextra, warn consumers of the fatal side effects, and withdraw the drug from the market even when the dangers became widely known. The lawsuit was filed in the Federal District Court for the Northern District of Illinois.

On April 7, Pfizer suspended sales of Bextra in the United States and the European Union. "The decision of the FDA to withdraw Bextra from the market is a victory for consumers, and affirms that the risks of these drugs outweigh the benefits," said Kenneth B. Moll. "However, countless individuals have already suffered severe or fatal injuries including heart attacks, strokes, embolisms, gastrointestinal bleeding, ulcers, and skin reactions such as Stevens-Johnson syndrome. This drug did not carry sufficient warnings regarding the potentially fatal side effects it can cause."

A study presented to the American Heart Association in November 2004 showed that patients taking Bextra were more than twice as likely to suffer a stroke or heart attack than those taking placebos. Two post-heart bypass surgery trials showed that Bextra triples the risk of cardiovascular events.

The lawsuit will seek compensation for those who have died and been injured as a result of their use of Bextra.

Kenneth B. Moll & Associates, one of the premier class action and mass tort law firms in the U.S.A., has already been contacted by hundreds of people from across America and around the world who have experienced these side effects. Last fall, KBM filed the first worldwide class action lawsuit against Merck & Co. following the recall of its Vioxx medication.


Kenneth B. Moll & Associates, Ltd., Chicago

Kenneth B. Moll, 312-558-6444

Fax: 312-558-1112